Repeatability of Magnetic Resonance Imaging in Patients with IDH1 Mutant Glioma on Ivosidenib - Clinical Trial
What is the Purpose of this Study?
We are doing this study to create a database of MRI images taken from patients with low-grade diffuse glioma who are being treated with ivosidenib. We want to use these images for analysis that might help us make better predictions about how we can expect tumors to grow for people diagnosed with low-grade diffuse glioma.
Low-Grade Diffuse Glioma
Who Can Participate in the Study?
Adults ages 18-70 who:
- Are diagnosed with IDH1 mutant low-grade glioma (WHO grade 2)
- Are currently taking ivosidenib
- Are able to have MRI scans
For more information, contact the study team at 919-684-5301.
What is Involved?
If you choose to join this study, you will have an MRI scan that is part of your clinical care. This will include a routine MRI scan with intravenous contrast agent using the Brain Tumor Imaging Protocol (BTIP). There will be additional research imaging sequences before this routine clinical care scan that will add about 15 minutes to the standard imaging time of 30 minutes to 1 hour.
You will take part in this study for only the one day during which you are scheduled to receive your MRI scan.
Study Details
